Elthera AG
Tailored cancer therapies
Elthera AG is developing antibodies against the novel target L1CAM, an adhesion molecule whose expression is strongly correlated with an aggressive tumor phenotype and poor prognosis in various types of cancer. Inhibition of L1CAM targets many mechanisms of tumor progression such as resistance to chemotherapy, escape from immunological control, formation of new blood vessels, tumor growth and metastases formation. By combining targeted anti-L1CAM therapy with companion diagnostics, Elthera will provide personalized treatment for patients with aggressive malignancies.
The therapies are using two approaches for an enhanced anti-cancer effect by distinct mechanisms of action: a T cell engaging anti-L1CAMxCD3 bispecific antibody and an antibody-drug conjugate for targeted tumor cell killing
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
14.02.2023
South Korean Biotech acquires first-in-class antibody from Elthera (startupticker.ch)
17.11.2020
Sino-Swiss Pitchinar – Venture Leaders China meet China’s innovative Guangdong Region (venturelab.swiss)
16.10.2020
Meet Elthera CEO Anne Schmidt and find out how she went back to her entrepreneurial roots (venturelab.swiss)
01.07.2020
Ten startups ready to take off to China (startupticker.ch)
01.07.2020
Meet the 10 Venture Leaders China 2020 (venturelab.swiss)
31.12.2020
PoC for ADC compound
31.12.2020
Desicion on clinical candidate
31.10.2020
MTA signed with at least one partner
No Jobs
Videos
Elthera video
Documents
TOP 100 Swiss Startup Award
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Venture Leaders China
The venture leaders - the members of the Swiss national startup team- have a clear-cut goal. They envision themselves as global players and want to take the first step to their global expansion. The ten-day business development program is specifically structured to help them achieve this goal.
Venture Leaders Life Sciences
The venture leaders - the members of the Swiss national startup team- have a clear-cut goal. They envision themselves as global players and want to take the first step to their global expansion. The ten-day business development program is specifically structured to help them achieve this goal.
Elthera AG
Tailored cancer therapies
Website:
www.elthera.com
Headquarter:
Schlieren
Foundation Date:
February 2016
Technology:
- Biotech
Sectors:
- Antibodies
- Biotech
- Cancer
- Diagnostics
- Protein drugs
Support received
